Angiogenic/osteogenic response of BMMSCs on bone-derived scaffold: Effect of hypoxia and role of PI3K/Akt-mediated VEGF-VEGFR pathway

Biotechnology Journal

Volumn 9, Issue 7, 2014, Pages 944-953

  Zhou, Yi ^a   Guan, Xiaoxu ^a   Yu, Mengfei ^a   Wang, Xinhua ^a   Zhu, Wenyuan ^a   Wang, Chaowei ^a   Yu, Mengliu ^a   Wang, Huiming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bone marrow derived mesenchymal stromal cells; Bone derived scaffolds; Hypoxia; PI3K Akt; Vascular endothelial growth factor

Indexed keywords

BONE; CELL ENGINEERING; ENDOTHELIAL CELLS; ENZYME ACTIVITY; REPAIR; TISSUE;

BONE MORPHOGENETIC PROTEIN-2; EFFECTIVE APPROACHES; HYPOXIA; MESENCHYMAL STROMAL CELLS; PI3K/AKT; TISSUE-ENGINEERED BONES; TISSUE-ENGINEERED SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

SCAFFOLDS (BIOLOGY);

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TISSUE SCAFFOLD; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; BONE TISSUE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HYPOXIA; IN VIVO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; ANIMAL; BONE; CELL HYPOXIA; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES; RAT; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT; TISSUE SCAFFOLD;

ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; MESENCHYMAL STROMAL CELLS; MICROSCOPY, ELECTRON, SCANNING; OSTEOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TISSUE SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903816671     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300310     Document Type: Article

References (50)

1. Muschler, G. F., Nakamoto, C., Griffith, L. G., Engineering principles of clinical cell-based tissue engineering. J. Bone Joint Surg. Am. 2004, 86-A, 1541-1558.
2. Hutmacher, D. W., Scaffolds in tissue engineering bone and cartilage. Biomaterials 2000, 21, 2529-2543.
3. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., Whitelaw, M. L., Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295, 858-861.
4. Breitbach, M., Bostani, T., Roell, W., Xia, Y. et al., Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007, 110, 1362-1369.
5. Yoon, Y. S., Park, J. S., Tkebuchava, T., Luedeman, C., Losordo, D. W., Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2004, 109, 3154-3157.
6. Williams, D. F., On the nature of biomaterials. Biomaterials 2009, 30, 5897-5909.
7. Fini, M., Motta, A., Torricelli, P., Giavaresi, G. et al., The healing of confined critical size cancellous defects in the presence of silk fibroin hydrogel. Biomaterials 2005, 26, 3527-3536.
8. Cowan, C. M., Soo, C., Ting, K., Wu, B., Evolving concepts in bone tissue engineering. Curr. Top. Dev. Biol. 2005, 66, 239-285.
9. Avci-Adali, M., Paul, A., Ziemer, G., Wendel, H. P., New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials. Biomaterials 2008, 29, 3936-3945.
10. Tadjoedin, E. S., de Lange, G. L., Bronckers, A. L., Lyaruu, D. M., Burger, E. H., Deproteinized cancellous bovine bone (Bio-Oss) as bone substitute for sinus floor elevation. A retrospective, histomorphometrical study of five cases. J. Clin. Periodontol. 2003, 30, 261-270.
11. Lee, H., Cusick, R. A., Browne, F., Ho, K. T. et al., Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices. Transplantation 2002, 73, 1589-1593.
12. Wu, C., Zhou, Y., Fan, W., Han, P. et al., Hypoxia-mimicking mesoporous bioactive glass scaffolds with controllable cobalt ion release for bone tissue engineering. Biomaterials 2012, 33, 2076-2085.
13. Mamalis, A. A., Cochran, D. L., The therapeutic potential of oxygen tension manipulation via hypoxia inducible factors and mimicking agents in guided bone regeneration. A review. Arch. Oral Biol. 2011, 56, 1466-1475.
14. Hung, S. C., Pochampally, R. R., Chen, S. C., Hsu, S. C., Prockop, D. J., Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25, 2363-2370.
15. 2 sensing. Science 2001, 292, 464-468.
16. Liu, Y., Berendsen, A. D., Jia, S., Lotinun, S. et al., Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J. Clin. Invest. 2012, 122, 3101-3113.
17. Li, X. D., Chen, J., Ruan, C. C., Zhu, D. L., Gao, P. J., Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts. Arterioscler. Thromb. Vasc. Biol 2012, 32, 2250-2258.
18. Li, G., Corsi-Payne, K., Zheng, B., Usas, A. et al., The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng. A 2009, 15, 2123-2133.
19. Harada, S., Rodan, G. A., Control of osteoblast function and regulation of bone mass. Nature 2003, 423, 349-355.
20. Deckers, M. M., Karperien, M., van der Bent, C., Yamashita, T. et al., Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000, 141, 1667-1674.
21. Deckers, M. M., van Bezooijen, R. L., van der Horst, G., Hoogendam, J. et al., Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002, 143, 1545-1553.
22. Chakraborty, G., Jain, S., Kundu, G. C., Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68, 152-161.
23. Dempke, W. C., Heinemann, V., Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer 2009, 45, 1117-1128.
24. Ping, Y. F., Yao, X. H., Jiang, J. Y., Zhao, L. T. et al., The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J. Pathol. 2011, 224, 344-354.
25. Wang, C., Lin, K., Chang, J., Sun, J., Osteogenesis and angiogenesis induced by porous beta-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways. Biomaterials 2013, 34, 64-77.
26. Zhou, Y., Guan, X. X., Zhu, Z. L., Guo, J. et al., Caffeine inhibits the viability and osteogenic differentiation of rat bone marrow-derived mesenchymal stromal cells. Br. J. Pharmacol. 2010, 161, 1542-1552.
27. Grayson, W. L., Zhao, F., Izadpanah, R., Bunnell, B., Ma, T., Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J. Cell Physiol. 2006, 207, 331-339.
28. Lee, Y. J., Karl, D. L., Maduekwe, U. N., Rothrock, C. et al., Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res. 2010, 70, 8357-8367.
29. Sun, J., Zhou, W., Ma, D., Yang, Y., Endothelial cells promote neural stem cell proliferation and differentiation associated with VEGF activated Notch and Pten signaling. Dev. Dyn. 2010, 239, 2345-2353.
30. Mistry, A. S., Mikos, A. G., Tissue engineering strategies for bone regeneration. Adv. Biochem. Eng. Biotechnol. 2005, 94, 1-22.
31. Lennon, D. P., Edmison, J. M., Caplan, A. I., Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J. Cell Physiol. 2001, 187, 345-355.
32. Grayson, W. L., Zhao, F., Bunnell, B., Ma, T., Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2007, 358, 948-953.
33. Martin-Rendon, E., Hale, S. J., Ryan, D., Baban, D. et al., Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells 2007, 25, 1003-1012.
34. Ren, H., Cao, Y., Zhao, Q., Li, J. et al., Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem. Biophys. Res. Commun. 2006, 347, 12-21.
35. Fehrer, C., Brunauer, R., Laschober, G., Unterluggauer, H. et al., Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 2007, 6, 745-757.
36. Potier, E., Ferreira, E., Andriamanalijaona, R., Pujol, J. P. et al., Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40, 1078-1087.
37. Hung, S. C., Pochampally, R. R., Hsu, S. C., Sanchez, C. et al., Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007, 2, e416.
38. Beck, G. J., Inorganic phosphate as a signaling molecule in osteoblast differentiation. J. Cell. Biochem. 2003, 90, 234-243.
39. Zelzer, E., Glotzer, D. J., Hartmann, C., Thomas, D. et al., Tissue specific regulation of VEGF expression during bone development requires Cbfa1/RUNX2. Mech. Dev. 2001, 106, 97-106.
40. Keramaris, N. C., Calori, G. M., Nikolaou, V. S., Schemitsch, E. H., Giannoudis, P. V., Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008, 39, 2, S45-S57.
41. Nakayama, M., Nakayama, A., van Lessen, M., Yamamoto, H. et al., Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell. Biol. 2013, 15, 249-260.
42. Wang, Y., Li, J., Wang, Y., Lei, L. et al., Effects of hypoxia on osteogenic differentiation of rat bone marrow mesenchymal stem cells. Mol. Cell. Biochem. 2012, 362, 25-33.
43. Salim, A., Nacamuli, R. P., Morgan, E. F., Giaccia, A. J., Longaker, M. T., Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J. Biol. Chem. 2004, 279, 40007-40016.
44. Kanichai, M., Ferguson, D., Prendergast, P. J., Campbell, V. A., Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: a role for AKT and hypoxia-inducible factor (HIF)-1alpha. J. Cell. Physiol. 2008, 216, 708-715.
45. Wang, Y., Wan, C., Deng, L., Liu, X. et al., The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 2007, 117, 1616-1626.
46. Das, M., Bouchey, D. M., Moore, M. J., Hopkins, D. C. et al., Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on g protein-mediated activation of mitogen-activated protein kinases. J. Biol. Chem. 2001, 276, 15631-15640.
47. Cross, M. J., Claesson-Welsh, L., FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 2001, 22, 201-207.
48. Niida, S., Kondo, T., Hiratsuka, S., Hayashi, S. et al., VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc. Natl. Acad. Sci. USA 2005, 102, 14016-14021.
49. Hutchings, H., Ortega, N., Plouet, J., Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. Faseb J. 2003, 17, 1520-1522.
50. Dai, J., Rabie, A. B., VEGF: an essential mediator of both angiogenesis and endochondral ossification. J. Dent. Res. 2007, 86, 937-950.